Cachet Pharmaceutical's low P/E ratio may be due to expectations of underperformance. Declining earnings and potential for further P/E drop could disappoint shareholders.
The company's high liabilities and decreasing ROCE are worrisome. Reinvestment has not led to significant sales growth. These trends are not typical for multi-baggers, suggesting investors may need to look elsewhere.
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Cachet Pharmaceutical Stock Forum
No comment yet